Effects of Pre-transplant Rapamycin Treatment and Tacrolimus Levels on the Outcome of Islet Transplantation Alone in Patients Receiving Edmonton Protocol.

Trial Profile

Effects of Pre-transplant Rapamycin Treatment and Tacrolimus Levels on the Outcome of Islet Transplantation Alone in Patients Receiving Edmonton Protocol.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2010

At a glance

  • Drugs Sirolimus (Primary) ; Daclizumab; Tacrolimus
  • Indications Islet cell transplant rejection
  • Focus Therapeutic Use
  • Acronyms ITA-Rp
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top